205 related articles for article (PubMed ID: 18499845)
1. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography.
Lyshchik A; Fleischer AC; Huamani J; Hallahan DE; Brissova M; Gore JC
J Ultrasound Med; 2007 Nov; 26(11):1575-86. PubMed ID: 17957052
[TBL] [Abstract][Full Text] [Related]
3. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of vulnerable plaques in rabbits using contrast-enhanced ultrasound targeting to vascular endothelial growth factor receptor-2.
Liu H; Wang X; Tan KB; Liu P; Zhuo ZX; Liu Z; Hua X; Zhuo QQ; Xia HM; Gao YH
J Clin Ultrasound; 2011 Feb; 39(2):83-90. PubMed ID: 21213333
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
[TBL] [Abstract][Full Text] [Related]
6. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound molecular imaging of vascular endothelial growth factor receptor 2 expression for endometrial receptivity evaluation.
Liu H; Chen Y; Yan F; Han X; Wu J; Liu X; Zheng H
Theranostics; 2015; 5(2):206-17. PubMed ID: 25553109
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
9. Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Mancini M; Greco A; Salvatore G; Liuzzi R; Di Maro G; Vergara E; Chiappetta G; Pasquinelli R; Brunetti A; Salvatore M
BMC Med Imaging; 2013 Sep; 13():31. PubMed ID: 24028408
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
[TBL] [Abstract][Full Text] [Related]
11. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
12. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).
Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W
Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592
[TBL] [Abstract][Full Text] [Related]
13. Effects of low-frequency ultrasound and microbubbles on angiogenesis-associated proteins in subcutaneous tumors of nude mice.
Shen ZY; Shen E; Zhang JZ; Bai WK; Wang Y; Yang SL; Nan SL; Lin YD; Li Y; Hu B
Oncol Rep; 2013 Aug; 30(2):842-50. PubMed ID: 23707983
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.
Pysz MA; Machtaler SB; Seeley ES; Lee JJ; Brentnall TA; Rosenberg J; Tranquart F; Willmann JK
Radiology; 2015 Mar; 274(3):790-9. PubMed ID: 25322341
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging.
Deshpande N; Ren Y; Foygel K; Rosenberg J; Willmann JK
Radiology; 2011 Mar; 258(3):804-11. PubMed ID: 21339349
[TBL] [Abstract][Full Text] [Related]
16. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
17. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis.
Rychak JJ; Graba J; Cheung AM; Mystry BS; Lindner JR; Kerbel RS; Foster FS
Mol Imaging; 2007; 6(5):289-96. PubMed ID: 18092513
[TBL] [Abstract][Full Text] [Related]
18. A method for assessing the microvasculature in a murine tumor model using contrast-enhanced ultrasonography.
Loveless ME; Li X; Huamani J; Lyshchik A; Dawant B; Hallahan D; Gore JC; Yankeelov TE
J Ultrasound Med; 2008 Dec; 27(12):1699-709. PubMed ID: 19022995
[TBL] [Abstract][Full Text] [Related]
19. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.
Warram JM; Sorace AG; Saini R; Umphrey HR; Zinn KR; Hoyt K
J Ultrasound Med; 2011 Jul; 30(7):921-31. PubMed ID: 21705725
[TBL] [Abstract][Full Text] [Related]
20. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).
Bzyl J; Lederle W; Rix A; Grouls C; Tardy I; Pochon S; Siepmann M; Penzkofer T; Schneider M; Kiessling F; Palmowski M
Eur Radiol; 2011 Sep; 21(9):1988-95. PubMed ID: 21562807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
